IP Library › Granted Patent US 10,407,496
Granted Patent B2
US 10,407,496 · App. 15/354,978 · Granted Sep 10, 2019

Compositions and methods for antibodies targeting complement protein C5

Inventors: Beate Diefenbach-Streiber (Windach, DE); Adina Eberth (Munich, DE); Braydon Charles Guild (Concord, MA); Yong-In Kim (Gyounggi-do, KR); Michael Roguska (Ashland, MA); Igor Splawski (Winchester, MA)
Assignee: Novartis AG
C07K16/18C07K2317/14C07K2317/21C07K2317/24C07K2317/55C07K2317/565C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,407,496
App. No.
15/354,978
Granted
Sep 10, 2019
Kind
B2
Abstract

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

Claims (12)

1. A method of inhibiting membrane attack complex (MAO formation in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising an isolated antibody or antigen binding fragment thereof that specifically binds to a human complement C5 protein, said antibody or antigen binding fragment thereof comprising an HCDR1 sequence comprising the sequence of SEQ ID NO: 1, an HCDR2 sequence comprising the sequence of SEQ ID NO: 2, an HCDR3 sequence comprising the sequence of SEQ ID NO: 3, an LCDR1 sequence comprising the sequence of SEQ ID NO: 4, an LCDR2 sequence comprising the sequence of SEQ ID NO: 5, and an LCDR3 sequence comprising the sequence of SEQ ID NO: 6, wherein the subject has asthma, arthritis, autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, Barraquer-Simons Syndrome, hemodialysis, systemic lupus, lupus erythematosus, psoriasis, multiple sclerosis, a transplantation, glomerulonephritis, or MPGN II.

2. The method of claim 1 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain variable region having 95% sequence identity to SEQ ID NO: 7.

3. The method of claim 1 wherein the antibody, or antigen binding fragment, further comprises a heavy chain variable region having the sequence of SEQ ID NO: 7.

4. The method of claim 1 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having 95% sequence identity to SEQ ID NO: 8.

5. The method of claim 3 , wherein the antibody, or antigen binding fragment, further comprises a light chain variable region having the sequence of SEQ ID NO:8.

6. The method of claim 1 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain having 95% sequence identity to SEQ ID NO: 9.

7. The method of claim 1 , wherein the antibody, or antigen binding fragment, further comprises a heavy chain having the sequence of SEQ ID NO: 9.

8. The method of claim 1 , wherein the antibody, or antigen binding fragment, further comprises a light chain having 95% sequence identity to SEQ ID NO: 10.

9. The method of claim 7 , wherein the antibody, or antigen binding fragment, further comprises a light chain having the sequence of SEQ ID NO: 10.

10. The method of claim 1 , wherein said subject is a human.

11. The method of claim 1 , wherein the MAC inhibition is associated with transplantation.

12. The method of claim 9 , wherein the MAC inhibition is associated with transplantation.

Continuity (6)
Division 15206916 · Jul 11, 2016
Continuation 14698039 · Apr 28, 2015
Continuation 13535612 · Jun 28, 2012
Continuation 12535205 · Aug 4, 2009
Provisional Application 61086355 · Aug 5, 2008
Related Publication 20170260260A1 · Sep 14, 2017